Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
AC Immune SA - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
ACIU
Nasdaq
8731
https://www.acimmune.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for AC Immune SA
AC Immune Holds Annual General Meeting of Shareholders
- Jun 24th, 2022 8:30 pm
10 Unknown Biotech Stocks That Can Explode in 2022
- Jun 21st, 2022 2:35 pm
Roche Alzheimer's Candidate Failure Hurts Lilly, Biogen
- Jun 17th, 2022 12:31 pm
Roche-AC Immune's Crenezumab Fails To Show Benefit In Sub-Set Of Alzheimer's Patients
- Jun 16th, 2022 12:20 pm
AC Immune shares slide 15% premarket after trial of Alzheimer's treatment misses its main goals
- Jun 16th, 2022 10:39 am
AC Immune Provides Update on Alzheimer’s Prevention Initiative Study Evaluating Crenezumab in Autosomal Dominant Alzheimer’s Disease
- Jun 16th, 2022 5:00 am
We're Not Very Worried About AC Immune's (NASDAQ:ACIU) Cash Burn Rate
- Jun 1st, 2022 12:26 pm
AC Immune to Present at the 2022 Jefferies Healthcare Conference
- May 31st, 2022 11:30 am
AC Immune CEO Andrea Pfeifer Receives Aenne Burda Award
- May 17th, 2022 1:00 pm
AC Immune’s Anti-Abeta Vaccine Results from Phase 1b Study in Down Syndrome Published in JAMA Neurology
- May 9th, 2022 3:00 pm
AC Immune Reports First Quarter 2022 Financial Results and Provides Corporate Update
- Apr 28th, 2022 11:30 am
AC Immune to Present at the B. Riley Annual Neuro & Ophthalmology Virtual Investor Conference
- Apr 27th, 2022 11:55 am
AC Immune Reports Changes to Senior Management
- Apr 8th, 2022 11:30 am
AC Immune KOL Webinar on First Clinical Proof of Concept for Alpha-synuclein Diagnostic Shows Breakthrough Potential for Neurodegenerative diseases
- Mar 30th, 2022 11:58 am
AC Immune Reports Full Year 2021 Financial Results and Provides Corporate Update
- Mar 22nd, 2022 11:30 am
AC Immune to Host Key Opinion Leader Webinar on Alpha-Synuclein as a Target in Neurodegenerative Diseases
- Mar 21st, 2022 11:30 am
AC Immune Reports First Live Images of Alpha-Synuclein in Human Brain with New PET Tracer for Neurodegenerative Disease at AD/PDTM Conference
- Mar 16th, 2022 11:41 am
AC Immune to Present at the AD/PD™ 2022 New Clinical and Preclinical Data for Alpha-Synuclein, Abeta and TDP-43 Programs
- Feb 28th, 2022 12:30 pm
Could The AC Immune SA (NASDAQ:ACIU) Ownership Structure Tell Us Something Useful?
- Feb 21st, 2022 9:30 am
AC Immune-Janssen Partnered Alzheimer's Vaccine Shows Tau-Specific Antibodies In Early-Stage Trial
- Feb 15th, 2022 7:54 pm
Scroll